Drugs / CIN-103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06153420 | Dec 2023 → Jul 2025 | irritable bowel syndrome | CinPhloro Pharma, LLC | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CIN-103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06153420 ↗ |
| Route | Oral | “Study drug taken twice daily by mouth.” NCT06153420 ↗ |